Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis
Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis
复制标题
DOI：
10.1111/j.1440-1746.1998.01553.x
复制
发表时间：
1998-03-01
影响因子：
4.1
通讯作者：
Asakura, H
中科院分区：
文献类型：
--
作者：
Itoh, S;Ichida, T;Asakura, H
据报道，针对210 kDa核孔复合物糖蛋白的抗核抗体（抗gp210）对原发性胆汁性肝硬化（PBC）具有高度特异性。本研究的目的是探讨抗gp210的意义，特别是作为预后标志物。用HepG2间接免疫荧光法测定113例PBC患者和162例对照患者中抗gp210的存在。使用HeLa细胞核提取物进行免疫印迹分析。113例患者中有25例（22.1%）检测到抗gp210。162例对照均无抗gp210阳性。PBC患者的抗gp210的出现和滴度在诊断时和整个临床过程中没有变化。113例PBC患者中有5例（4.4%）未检测到抗线粒体抗体（AMA），包括针对丙酮酸脱氢酶复合物、支链a-酮酸脱氢酶复合物和或-酮戊二酸脱氢酶复合物的抗体。然而，这5例患者中有1例仅抗gp210阳性。两组预后差异有统计学意义；PBC抗gp210阳性患者死于肝功能衰竭的频率高于阴性患者（P < 0.01），但两组在黄疸发生频率和诊断时的组织学分期方面差异无统计学意义。我们认为，抗gp210的存在是能够在诊断时预测PBC患者预后不良的独立预后指标之一。
It has been reported that the presence of anti-nuclear antibody against a 210 kDa glycoprotein of nuclear pore complex (anti-gp210) is highly specific for primary biliary cirrhosis (PBC). The aim of the present study was to investigate the significance of anti-gp210, especially as a prognostic marker. The presence of anti-gp210 was ascertained in 113 patients with PBC and 162 controls by indirect immunofluorescence assay using HepG2. cells and immunoblotting analysis using nuclear extracts from HeLa cells. Anti-gp210 was detected in 25 of the 113 (22.1%) patients. None of the 162 controls was positive for anti-gp210. The appearance and titre of anti-gp210 in the patients with PBC did not vary from the time of diagnosis and through their clinical course. Anti-mitochondrial antibodies (AMA), including antibodies against pyruvate dehydrogenase complex, branched chain a-ketoacid dehydrogenase complex and or-ketoglutarate dehydrogenase complex, were not detected by enzyme-linked immunosorbent assay in five of the 113 (4.4%) patients with PBC. However, anti-gp210 alone was positive in one of these five patients. The difference in prognosis was statistically significant; patients with PBC positive for anti-gp210 died from hepatic failure more frequently than those who were negative (P < 0.01), although there were no statistically significant differences in the frequency of jaundice and the histological stage at the time of diagnosis between the two groups. We suggest that the presence of anti-gp210 is one of the independent prognostic markers able to predict, at the time of diagnosis, a poor outcome in patients with PBC.